Are you over 18 and want to see adult content?
More Annotations
![RailsApps · Build and Learn · Examples and Tutorials](https://www.archivebay.com/archive/9e7aa8fa-f7e7-4050-8346-865988d2c904.png)
RailsApps · Build and Learn · Examples and Tutorials
Are you over 18 and want to see adult content?
![Effective Software Design | Doing the right thing.](https://www.archivebay.com/archive/55543069-5b62-4dad-9157-c6b351e7f0d6.png)
Effective Software Design | Doing the right thing.
Are you over 18 and want to see adult content?
![Latest Himachal News in Hindi - Himachal Abhi Abhi](https://www.archivebay.com/archive/903711b9-2c8e-4f4a-ae58-82d1a90a3515.png)
Latest Himachal News in Hindi - Himachal Abhi Abhi
Are you over 18 and want to see adult content?
![ГДЗ Грамота - готовые домашние задание для младших классов по литературному чтению](https://www.archivebay.com/archive/dea79cef-6354-441f-8e8f-3df042781a70.png)
ГДЗ Грамота - готовые домашние задание для младших классов по литературному чтению
Are you over 18 and want to see adult content?
![Erin Moy | A short selection of published writing, short films and events](https://www.archivebay.com/archive/66cc0bf4-7a4b-4b6c-ba87-42673f2bab71.png)
Erin Moy | A short selection of published writing, short films and events
Are you over 18 and want to see adult content?
![Un cours de mathématiques du Collège au Lycée](https://www.archivebay.com/archive/8d66984b-8c93-455b-8898-f5cbc44a5dd0.png)
Un cours de mathématiques du Collège au Lycée
Are you over 18 and want to see adult content?
![PULSER - ноутбуки, компьютеры, комплектующие, периферия, оргтехника, серверы в Алматы](https://www.archivebay.com/archive/c67f1805-444e-4dcf-9122-df3e7caf9754.png)
PULSER - ноутбуки, компьютеры, комплектующие, периферия, оргтехника, серверы в Алматы
Are you over 18 and want to see adult content?
![Quick & Easy Recipes using gadgets in the modern kitchen - Piping Pot Curry](https://www.archivebay.com/archive/33dc8179-7b8f-4a1e-9a06-7e4b788b9743.png)
Quick & Easy Recipes using gadgets in the modern kitchen - Piping Pot Curry
Are you over 18 and want to see adult content?
Favourite Annotations
![Venta y Arriendo de Propiedades - ZoomInmobiliario.com](https://www.archivebay.com/archive/debe99c4-48bb-419c-b9a5-bc6fb6bd7baf.png)
Venta y Arriendo de Propiedades - ZoomInmobiliario.com
Are you over 18 and want to see adult content?
![A complete backup of animewrld7.blogspot.com](https://www.archivebay.com/archive/57fbfd17-e4dc-461a-b31a-a1b9c3666761.png)
A complete backup of animewrld7.blogspot.com
Are you over 18 and want to see adult content?
![МотоВело техника. Запчасти SYM - Velocityk](https://www.archivebay.com/archive/2c908ab0-2f8f-4c16-9280-1c834e9a4542.png)
МотоВело техника. Запчасти SYM - Velocityk
Are you over 18 and want to see adult content?
![Certificazione Halal | HIA ente di Certificazione Islamica internazionale](https://www.archivebay.com/archive/f735baaf-811b-4c0a-b04c-cd7c331110e5.png)
Certificazione Halal | HIA ente di Certificazione Islamica internazionale
Are you over 18 and want to see adult content?
![Your Naturist Holiday Starts Here! | Naturist BnB](https://www.archivebay.com/archive/f89e47a2-c85b-4c0e-97cb-f60e017c01da.png)
Your Naturist Holiday Starts Here! | Naturist BnB
Are you over 18 and want to see adult content?
![Športtestery, cyklistika, beh, plávanie, fitness a doplnky výživy | pro-body.sk](https://www.archivebay.com/archive/cf48945b-1d1d-46c8-86fb-27f69e2339b7.png)
Športtestery, cyklistika, beh, plávanie, fitness a doplnky výživy | pro-body.sk
Are you over 18 and want to see adult content?
![Renaissance Periodization](https://www.archivebay.com/archive/fca3b9e9-3311-4939-9359-8014c46d42a6.png)
Renaissance Periodization
Are you over 18 and want to see adult content?
![Freeride Boardshop | Canadian Snowboard, Skateboard & Wakeboard Store](https://www.archivebay.com/archive/c9a7e105-74a3-4fbe-826f-e3cac024835b.png)
Freeride Boardshop | Canadian Snowboard, Skateboard & Wakeboard Store
Are you over 18 and want to see adult content?
![Air Conditioning Installation Dubai | AC Maintenance in Dubai](https://www.archivebay.com/archive/53dd5a6e-8fcd-4501-a264-ae9440cc22c2.png)
Air Conditioning Installation Dubai | AC Maintenance in Dubai
Are you over 18 and want to see adult content?
Text
Hospital of UPMC,
LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC A PHASE III TRIAL OF SURGERY WITH OR WITHOUT ADJUNCTIVE The primary outcome, recurrence-free interval (RFI), is defined as the time from study entry to clinical, histologic, or radiographic evidence of disease recurrence. HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
THE GORE-TEX SURGICAL MEMBRANE: EFFECTIVENESS AS A BARRIER GYNECOLOGIC ONCOLOGY 45, 290-293 (1992) The Gore-Tex Surgical Membrane: Effectiveness as a Barrier to Inhibit Postradical Pelvic Surgery Adhesions in a Porcine Model’ PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC63 At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC A PHASE III TRIAL OF SURGERY WITH OR WITHOUT ADJUNCTIVE The primary outcome, recurrence-free interval (RFI), is defined as the time from study entry to clinical, histologic, or radiographic evidence of disease recurrence. HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
THE GORE-TEX SURGICAL MEMBRANE: EFFECTIVENESS AS A BARRIER GYNECOLOGIC ONCOLOGY 45, 290-293 (1992) The Gore-Tex Surgical Membrane: Effectiveness as a Barrier to Inhibit Postradical Pelvic Surgery Adhesions in a Porcine Model’ PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial 51ST ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGY The Society of Gynecologic Oncology (SGO) was scheduled to conduct its 2020 Annual Meeting on Women's Cancer®, March 28–31, in Toronto, Canada. Due to the COVID-19 global pandemic, SGO decided not to conduct its annual meeting for the first time in its history. On March 28, SGO released all annual meeting abstracts to the general public, and in April launched a series of free webinars to ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. NEOADJUVANT CHEMOTHERAPY FOLLOWED BY POST-PARTUM Cervical cancer is the most common malignancy in pregnancy with an incidence of 1.2–10.6 per 10,000 pregnancies. We report a case of FIGO stage IIIB glassy cell carcinoma (GCC) of the cervix presenting during pregnancy. This is the first report of a successful outcome with this histologic type of cervical cancer presenting at an advanced stage during pregnancy. THE GORE-TEX SURGICAL MEMBRANE: EFFECTIVENESS AS A BARRIER GYNECOLOGIC ONCOLOGY 45, 290-293 (1992) The Gore-Tex Surgical Membrane: Effectiveness as a Barrier to Inhibit Postradical Pelvic Surgery Adhesions in a Porcine Model’ BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard TREATMENT RELATED OUTCOMES IN HIGH-RISK ENDOMETRIAL Multivariable Cox regression analysis for stage 1 and 2 disease in women with ESC revealed that increasing patient age and presence of LVI were predictors of decreased OS. ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. 51ST ANNUAL MEETING OF THE SOCIETY The Society of Gynecologic Oncology (SGO) was scheduled to conduct its 2020 Annual Meeting on Women's Cancer®, March 28–31, in Toronto, Canada. Due to the COVID-19 global pandemic, SGO decided not to conduct its annual meeting for the first time in its history. On March 28, SGO released all annual meeting abstracts to the general public, and in April launched a series of free webinars to ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
A PHASE II TRIAL OF PEMBROLIZUMAB IN COMBINATION WITH Method: This is an open-label phase II study (with a safety lead-in cohort of n = 5) of pembrolizumab 200 mg IV in combination with bevacizumab 15 mg/kg IV every 3 weeks and oral cyclophosphamide 50 mg every day until disease progression or unacceptable toxicity. Key eligibility included RECIST 1.1 measurable platinum-resistant recurrent ovarian cancer or patient declines AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard CURRENT STATUS OF THERAPEUTIC HPV VACCINES Invited Review Current status of therapeutic HPV vaccines Katharine T. Clark, Cornelia L. Trimble⁎ Department of Gynecology and Obstetrics, Johns Hopkins University, School of PHASE II TRIAL OF VINORELBINE FOR RELAPSED OVARIAN CANCER Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study Mace L. Rothenberga,*, P.Y. Liub, Sharon Wilczynskic, William A. Nahhasd ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- HOME PAGE: GYNECOLOGIC ONCOLOGY The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women's cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. 51ST ANNUAL MEETING OF THE SOCIETY The Society of Gynecologic Oncology (SGO) was scheduled to conduct its 2020 Annual Meeting on Women's Cancer®, March 28–31, in Toronto, Canada. Due to the COVID-19 global pandemic, SGO decided not to conduct its annual meeting for the first time in its history. On March 28, SGO released all annual meeting abstracts to the general public, and in April launched a series of free webinars to ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard A PHASE II TRIAL OF PEMBROLIZUMAB IN COMBINATION WITH Method: This is an open-label phase II study (with a safety lead-in cohort of n = 5) of pembrolizumab 200 mg IV in combination with bevacizumab 15 mg/kg IV every 3 weeks and oral cyclophosphamide 50 mg every day until disease progression or unacceptable toxicity. Key eligibility included RECIST 1.1 measurable platinum-resistant recurrent ovarian cancer or patient declines MTOR INHIBITORS AND THEIR CLINICAL APPLICATION IN CERVICAL Review mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review Nader Husseinzadeha,⁎, Holleh D. Husseinzadehb a Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Cincinnati, 231 Albert Sabin Way Cincinnati, OH 45267-0526, USA b Abramson Cancer Center, Division of Hematology-Oncology, University of PHASE II TRIAL OF ALTERNATING COURSES OF MEGESTROL ACETATE Objectives. To estimate the objective response rate and toxicity associated with alternating megestrol acetate (MA) and tamoxifen citrate (T) in women with endometrial carcinoma.Methods. Consenting patients with measurable recurrent or advanced endometrial carcinoma were eligible if they had not received prior cytotoxic or hormonal treatment. MA 80 mg BID × 3 weeks alternating with T 20 WEEKLY TOPOTECAN FOR RECURRENT ENDOMETRIAL CANCER: A CASE Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature Tiffany A. Traina, Paul Sabbatini, Carol Aghajanian, Jakob Dupont* PHASE II TRIAL OF VINORELBINE FOR RELAPSED OVARIAN CANCER Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study Mace L. Rothenberga,*, P.Y. Liub, Sharon Wilczynskic, William A. NahhasdDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0